Hospital 30-day Readmission Rates in Patients with Decompensated Cirrhosis: A Nationwide Sample
AASLD LiverLearning®, George Cholankeril, 144650
Differential Access to Direct Acting Antivirals (DAAs) Across Federal, State, Commercial, and Manufacturer Patient Assistance Programs (MPAP)
AASLD LiverLearning®, Jane Giang, 144651
Perceptions of HCV treatment and correlates to initiation willingness in HCV+ methadone clients
AASLD LiverLearning®, Amy Jessop, 144652
Treatment of chronic HCV infection with the new direct acting antivirals (DAAs): a Real World experience in Brazil.
AASLD LiverLearning®, Hugo Cheinquer, 144908
Symptom Clusters Generated using Factorial Analysis of PROMIS tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144653
Effectiveness and security of 3D/2D treatment in HCV/HIV coinfected cirrhotic patients
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
AASLD LiverLearning®, Eli Zuckerman, 144910
Efficacy and safety of Telbivudine or Tenofovir use in second to third trimester preventing vertical transmission of hepatitis B virus in real-life practice
AASLD LiverLearning®, Jinfeng Liu, 144666
Comparative Efficacy of an Intensified Re-Vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected with HIV (CORE-HIV): A Randomized Controlled Trial. Interim Analysis.
AASLD LiverLearning®, Jose Ignacio Vargas, 144667
Early hepatitis B surface antigen seroclearance after commencement of antiviral treatment in patients with de novo HBV reactivation
AASLD LiverLearning®, Haelim Lee, 144668
Spontaneous Bacterial Peritonitis in cirrhosis: a Prospective Multicenter Study of Clinical, Microbiological characteristics and Predictors of 6 months Survival
AASLD LiverLearning®, Dimitrios Samonakis, 144924
The role of IL-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection
AASLD LiverLearning®, Lung Yi Mak, 144669
Infection with multi-drug resistant organisms is associated with increased mortality in patients listed for liver transplantation.
AASLD LiverLearning®, Rosalie C. Oey, 144925
Early Fluid Resuscitation in Cirrhotic Patients Diagnosed with Severe Sepsis is Associated with Decreased In-Hospital Mortality
AASLD LiverLearning®, James Crismale, 144926
Progression to liver-related complications in HIV/hepatitis B coinfected patients in the era of potent combination antiretroviral therapy (cART) is not increased compared to hepatitis B mono-infection
AASLD LiverLearning®, Faydra Lieveld, 144682
Quantitative Hepatitis B Surface Antigen Does Not Reliably Identify Patients with Active Hepatitis D Virus Infection
AASLD LiverLearning®, Matthew Sadler, 144683
Combined use of AST to platelet ratio index and Fibrosis-4 score can risk stratify hepatocellular carcinoma risk in chronic hepatitis B patients with low level viremia
AASLD LiverLearning®, Ji Hyeon Lee, 144684
Drug resistant infections in hospitalized patients with cirrhosis are nosocomial and associated with renal and respiratory failure: Results from NACSELD.
AASLD LiverLearning®, Jasmohan S. Bajaj, 144940
US Asian HBV Patients Have Liver Steatosis and Metabolic Syndrome at Lower BMI than non Asians
AASLD LiverLearning®, William Clarke, 144685
Improved short-term survival in patients with Acute-on-Chronic Liver Failure (ACLF) in extremis with a combination therapy approach
AASLD LiverLearning®, Gaurav Pande, 144941
Opioid use is associated with all-cause and sepsis-related death among patients with cirrhosis
AASLD LiverLearning®, Steven Scaglione, 144942
Risk for progressing to immune active (IA) phase chronic hepatitis B virus infection (CHB) among Alaska Native (AN) persons in the inactive carrier (IC) and indeterminate CHB infection phases — Alaska, 2001-2014.
AASLD LiverLearning®, Prabhu Gounder, 144698
Hepatitis B surface antigen titer is a good indicator of durable viral response after off-treatment of entecavir for chronic hepatitis B
AASLD LiverLearning®, Hanah Lee, 144699
Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
AASLD LiverLearning®, Yuanyuan Kong, 144700
Oral Rifaximin Soluble Solid Dispersion Immediate-Release 40 mg Prevents Development of Cirrhosis-Related Complications: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144956
Prediction of hepatitis B virus-related liver cancer incidence and recurrence after anticancer therapy by hybrid evaluation of serum WFA(+)-M2BP and hepatitis B core-related antigen
AASLD LiverLearning®, Kazunori Kawaguchi, 144701
Assess outcome of Slow low-dose continuous albumin,Furosemide with or without Terlipressin SIFA(T) infusion in patients of cirrhosis with refractory ascites
AASLD LiverLearning®, Gaurav Pande, 144957
Fatty acid-binding proteins (FABPs) levels are increased in decompensated cirrhosis and associated with poor outcomes
AASLD LiverLearning®, Isabel Graupera, 144958
Effect of Glucocorticoid on Hepatitis B Virus Reactivation in HBsAg-positive Rheumatoid Arthritis Patients undergoing Biologics Treatment
AASLD LiverLearning®, Yi-Hsiang Huang, 144715
The SNPs of HLA-DP are associated with HBsAg levels in chronic HBV infection
AASLD LiverLearning®, Ochi Yuka, 144716
Urinary NGAL biomarker predicts non response to therapy with albumin and terlipressin in patients with hepatorenal syndrome
AASLD LiverLearning®, Rafael Ximenes, 144972
Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA
AASLD LiverLearning®, Jens Verheyen, 144717
TLR-9 rs187084-dependent reduction of inflammatory and sympathetic responses to bacterial translocation in patients with decompensated cirrhosis
AASLD LiverLearning®, Paula PIÑERO ROMERO, 144973
Serum microRNA-122 as well as WFA(+)-M2BP is a good predictor of liver fibrosis in chronic hepatitis B infection
AASLD LiverLearning®, Masato Nakamura, 144718
Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
AASLD LiverLearning®, Troels Busk, 144974
Diagnostic performance of APRI, FIB-4 and Fibroscan for assessment of hepatic fibrosis in chronic hepatitis B patients receiving oral antiviral therapy; 7-year real life data
AASLD LiverLearning®, Iftihar Köksal, 144731
Validation of a Mortality Risk Score to assess the Long-Term Prognosis of Chronic Hepatitis B Patients
AASLD LiverLearning®, Willem Pieter Brouwer, 144732
Safety and efficacy of prolonged low dose thrombolysis for acute non-malignant and non-cirrhotic splanchnic venous thrombosis
AASLD LiverLearning®, Pathik Parikh, 144988
Switching to Tenofovir versus Continuing Entecavir in Chronic Hepatitis B Patients with Partial Virologic Response during Entecavir Therapy: STEEP Study
AASLD LiverLearning®, Hyung Joon Yim, 144733
The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression
AASLD LiverLearning®, Jordi Gracia-Sancho, 144989
Predictive role of serum HBsAg and HBcrAg levels in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon-based therapy
AASLD LiverLearning®, Pisit Tangkijvanich, 144734
Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases
AASLD LiverLearning®, Akiko Eguchi, 144990
Intrahepatic persistence of hepatitis B virus covalently closed circular DNA (cccDNA) after 3 to 5 years of telbivudine therapy for chronic hepatitis B (CHB)
AASLD LiverLearning®, Fabien Zoulim, 144747
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
AASLD LiverLearning®, Wan-Long Chuang, 144748
Bowel wall thickness and elasticity, Intestinal Permeability and Serum Inflammatory Mediators in Patients with Decompensated Liver Cirrhosis
AASLD LiverLearning®, Sang Hyuk Lee, 145004
Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Maurizia Rossana Brunetto, 144749
Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients
AASLD LiverLearning®, Patrick Marcellin, 144750
Impact of Antiviral Nucleotide Analogues on Age-Dependent Decline in Renal Function
AASLD LiverLearning®, Prowpanga Udompap, 144763
A Retrospective Study on the Clearance Rate of Hepatitis B Surface Antigen with Antivirus Treatment in 1 to 7 years old Children with HBeAg-positive Chronic Hepatitis B
AASLD LiverLearning®, Zhu Shishu, 144764
A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
AASLD LiverLearning®, JANG BYOUNG KUK, 144765
A real-world experience in baseline predictors of virological response to Peginterferon Alfa-2a in patients with HBeAg-negative chronic hepatitis B
AASLD LiverLearning®, Yi-Cheng Chen, 144766
Tenofovir disoproxil fumarate Monotherapy is superior to Entecavir-adefovir Combination in Suboptimal Responder for Lamivudine-adefovir Therapy in Chronic Hepatitis B Patients with rt204I/V Mutation: a 96-Week Prospective Multicenter Trial
AASLD LiverLearning®, Sae Hwan Lee, 144780
A randomized study comparing tenofovir dispoxil fumarate and entecavir hydrate in Japanese patients with treatment naïve chronic hepatitis B
AASLD LiverLearning®, Wataru Sugiura, 144781
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemo-embolization
AASLD LiverLearning®, Sun Hong Yoo, 144782
Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH)
AASLD LiverLearning®, Lin Lee Wong, 144539
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Autoimmune Hepatitis
AASLD LiverLearning®, Christopher O'Brien, 144540
Characterization Of Changes In FibroTest Values During Treatment With Tenofovir Alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) In Patients With CHB
AASLD LiverLearning®, Namiki Izumi, 144796
Prevalence and Predictors of Fragility Fracture in Corticosteroid-treated Patients with Autoimmune Hepatitis (AIH)
AASLD LiverLearning®, Laura Harrison, 144541
Liver stiffness and virologic outcomes after introducing tenofovir as part of antiretroviral therapy in lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana: four-year follow up of the prospective HEPIK cohort
AASLD LiverLearning®, Alexander Stockdale, 144797
Analysis of the incidence of primary hepatocellular carcinoma in Japanese patients with hepatitis B virus infection stratified by primary liver cancer risk score at the start of Entecavir therapy
AASLD LiverLearning®, Yoshiyasu Karino, 144798
UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis
AASLD LiverLearning®, Lin Lee Wong, 144555
RNA-seq analysis identifies early gene signature associated with antifibrotic efficacy of dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1 (ASK1) in BALBc.Mdr2-/- mice
AASLD LiverLearning®, Yury Popov, 144556
The influence of clinical significant portal hypertension (stage Baveno 2) on safety, tolerability and efficacy of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin (PrOD+R) in a real-world large cohort of genotype 1b HCV liver cirrhosis patien
AASLD LiverLearning®, Anca Trifan, 144812
IL-4 and IL-13 regulate liver fibrosis through M2 macrophages, but not Th2 T cells or hepatocytes
AASLD LiverLearning®, Shih-yen Weng, 144557
Predictors of Sustained Virological Response (SVR) after Direct Acting Antiviral (DAA) treatment for Hepatitis C: meta-analysis of 55 studies in 11,419 patients
AASLD LiverLearning®, Bryony Simmons, 144813
Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
AASLD LiverLearning®, Taeang Arai, 144814
Advanced glycation end products and dysregulated RAGE/AGER1 induce proinflammatory and fibrogenic signaling in NASH via NOX4
AASLD LiverLearning®, Ali Dehnad, 144571
Anti-fibrotic and anti-inflammatory effect of a novel LPA1 receptor antagonist, UD-009, in a mouse model of NASH.
AASLD LiverLearning®, Kenji Nishikawa, 144572
Current treatment options with direct acting antivirals in HCV genotype 3 infections - still room for improvement? Results from the German multicenter GECCO cohort.
AASLD LiverLearning®, Julian Schulze zur Wiesch, 144828
Mice with genetic deletion of ecto-nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) are protected from development of both biliary and parenchymal-type liver fibrosis
AASLD LiverLearning®, Linda Feldbrugge, 144573
Effect of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection with RAV negative population; from real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144829
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis or bridging fibrosis treated with different SOF-based DAA regimens: a single centre experience with a mean follow up of 12 months
AASLD LiverLearning®, Alessandra Mangia, 144830
Hepatic stellate cell Yes-associated protein 1 (Yap1) is necessary for liver regeneration
AASLD LiverLearning®, Anna Mae Diehl, 144586
Disruption of Heat Shock Transcription Factor 1 (HSF1) reveals its essential role in protection from liver inflammation and fibrosis
AASLD LiverLearning®, Asmita Choudhury, 144587
Caveolin-1 targets lipid droplets formation in human hepatic stellate cells
AASLD LiverLearning®, Hiroaki Yokomori, 144588
Regression of liver fibrosis following Sustained Viral response (SVR) with Interferon(IFN)-free HCV treatment
AASLD LiverLearning®, Barbara Menzaghi, 144844
Th2-polarization of CD4+ T-cells is locally induced and drives liver fibrogenesis
AASLD LiverLearning®, Johanna Reissing, 144589
The impact of IL28B polymorphism and HCV NS5A resistance associated variants on treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings
AASLD LiverLearning®, Hitomi Sezaki, 144845
Uptake of HCV Therapy in HIV/HCV Coinfected Patients across Europe in the Era of Direct-Acting Antivirals
AASLD LiverLearning®, Lars Peters, 144846
MELD-HE score: a new model to predict risk of mortality in variceal bleeding
AASLD LiverLearning®, Marika Rudler, 144602
Endoscopic Screening for large varices: increase in MELD score more predictive of variceal growth than calendar year
AASLD LiverLearning®, Sakkarin Chirapongsathorn, 144603
The comparison of long-term survival in cirrhotic patients with significant ascites and esophageal varices according to the treatment modality between endoscopic variceal ligation and non-selective beta-blockers
AASLD LiverLearning®, Jeong-Ju Yoo, 144604
Premature Discontinuation of Direct Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) in Real World Clinical Practice
AASLD LiverLearning®, Jasmine Hanifi, 144860
Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease: a meta-analysis
AASLD LiverLearning®, Xiaowen Ma, 144605
Sofosbuvir plus Ribavirin for difficult to treat HCV-2 : improved efficacy with extended treatment duration
AASLD LiverLearning®, Sara Piovesan, 144861
Efficacy and safety of the currently recommended regimens with direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, George Papatheodoridis, 144862
Comparing the Inpatient Disease Burden of HCV and HIV Infections: Trends in Hospitalization, Cost of Care, and Length of Stay
AASLD LiverLearning®, George Cholankeril, 144618
Extensive Economic and Quality of Life Burden of Viral Hepatitis (VH): The Data from the U.S. Medical Expenditure Panel Survey (MEPS)
AASLD LiverLearning®, Zobair Younossi, 144619
Factors associated with survival in a population-based cohort of patients with end-stage liver disease
AASLD LiverLearning®, David Goldberg, 144620
Baseline and post-treatment hepatitis C NS5A resistance analysis in relapsed patients from a multicentric real life cohort of 2740 patients exposed to NS5A inhibitor
AASLD LiverLearning®, Philippe Halfon, 144876
Impact of hepatitis C virus reflex testing on the hepatitis C care continuum among baby boomers in a urban health system
AASLD LiverLearning®, Aparna Goel, 144621
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: the Canadian National Experience.
AASLD LiverLearning®, Bandar Aljudaibi, 144877
Safety and efficacy of Interferon-free antiviral treatment in Hepatitis C patients with MELD score 20 and over
AASLD LiverLearning®, Carmen Vinaixa, 144878
Changes in liver biopsy training requirements to reflect competency-based medical education concepts
AASLD LiverLearning®, Oren Fix, 144634
Patient reported assessment of different diagnostic imaging tests for liver disease - visual representation and ownership of results improves understanding.
AASLD LiverLearning®, Andrew McKay, 144635
Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection
AASLD LiverLearning®, Brian McMahon, 144636
Factors that influence the improvement of liver albumin synthesis during interferon-free sofosbuvir-based therapy of chronic hepatitis C virus infection
AASLD LiverLearning®, Akira Kawano, 144892
Improving Age-Based Hepatitis C Screening at a Veterans Affairs Primary Care Clinic
AASLD LiverLearning®, Jessica Rubin, 144637
Efficacy of direct-acting antiviral agents for treatment of HCV genotype 1 infection in Hispanics: data from a real-world cohort.
AASLD LiverLearning®, Andres Carrion, 144893
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials
AASLD LiverLearning®, Stefan Mauss, 144894